Park Place Capital’s Edwards Lifesciences EW Stock Holding History

Park Place Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.37K	Sell	92 -5	-5%	-$412	﹤0.01%	639
2025 Q4	$8.27K	Hold	97	–	–	﹤0.01%	601
2025 Q3	$7.54K	Buy	97 +31	+47%	+$2.42K	﹤0.01%	600
2025 Q2	$5.09K	Hold	66	–	–	﹤0.01%	658
2025 Q1	$4.78K	Sell	66 -2	-3%	-$143	﹤0.01%	669
2024 Q4	$5.03K	Sell	68 -30	-31%	-$2.1K	﹤0.01%	669
2024 Q3	$6.47K	Sell	98 -181	-65%	-$13.2K	﹤0.01%	681
2024 Q2	$25.8K	Sell	279 -1,085	-80%	-$96.1K	0.01%	458
2024 Q1	$130K	Sell	1,364 -1,353	-50%	-$114K	0.05%	285
2023 Q4	$207K	Sell	2,717 -1,222	-31%	-$85K	0.08%	216
2023 Q3	$273K	Sell	3,939 -120	-3%	-$9.64K	0.08%	200
2023 Q2	$383K	Sell	4,059 -745	-16%	-$64.8K	0.11%	171
2023 Q1	$397K	Sell	4,804 -470	-9%	-$36.9K	0.11%	171
2022 Q4	$393K	Buy	+5,274	New	+$406K	0.11%	171

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Park Place Capital's EW Position: Q1 2026 in Review

Park Place Capital reduced its Edwards Lifesciences (EW) stake by 5.2% in Q1 2026, selling an estimated $412 and leaving 92 shares worth $7.37K. The position accounts for ﹤0.01% of the portfolio, ranked #639.

Park Place Capital first reported a position in EW in Q4 2022 and has held it in 14 quarters since. The position peaked at $397K in Q1 2023. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Park Place Capital held 92 shares of Edwards Lifesciences worth $7.37K as of Q1 2026.
Park Place Capital sold 5 Edwards Lifesciences shares in Q1 2026, an estimated $412.
Edwards Lifesciences made up ﹤0.01% of Park Place Capital's portfolio in Q1 2026, its #639 holding.
Park Place Capital first reported a position in Edwards Lifesciences in Q4 2022 and has held it in 14 quarters since.
Park Place Capital's Edwards Lifesciences position peaked at $397K in Q1 2023.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Park Place Capital's 13F filing for Q1 2026, filed 9 Apr 2026.